# Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer

> **NCT02117817** · PHASE1 · WITHDRAWN · sponsor: **Rutgers, The State University of New Jersey**

## Conditions studied

- Ovarian Cancer
- Endometrial Cancer
- Recurrent Ovarian Cancer
- Recurrent Endometrial Cancer

## Interventions

- **DRUG:** BKM120
- **DRUG:** Nabpaclitaxel

## Key facts

- **NCT ID:** NCT02117817
- **Lead sponsor:** Rutgers, The State University of New Jersey
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-02
- **Primary completion:** 2015-02-25
- **Final completion:** 2015-02-25
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Research cancelled
- **Last updated:** 2022-07-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02117817

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02117817, "Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02117817. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*